UY35801A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
UY35801A
UY35801A UY0001035801A UY35801A UY35801A UY 35801 A UY35801 A UY 35801A UY 0001035801 A UY0001035801 A UY 0001035801A UY 35801 A UY35801 A UY 35801A UY 35801 A UY35801 A UY 35801A
Authority
UY
Uruguay
Prior art keywords
compound
salt
heterocyclic compound
medicament
sstr5
Prior art date
Application number
UY0001035801A
Other languages
English (en)
Inventor
Yamasaki Takeshi
Nishikawa Yoichi
Kina Asato
Nakahata Takashi
Yamashita Tohru
hirose Hideki
Kasai Shizuo
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY35801A publication Critical patent/UY35801A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporciona un compuesto que tiene una acción antagonista del SSTR5 y el uso del compuesto como medicamento. De forma específica, se proporciona un compuesto representado por la fórmula que aparece a continuación: en donde cada símbolo es como s e lo define en la presente, o una sal de él, un medicamento que comprende el compuesto o una sal de él, y el uso del compuesto o una sal de él como agente para la profilaxis o el tratamiento de la diabetes mellitus.
UY0001035801A 2013-10-29 2014-10-28 Compuesto heterocíclico UY35801A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013224093 2013-10-29

Publications (1)

Publication Number Publication Date
UY35801A true UY35801A (es) 2015-06-30

Family

ID=51932560

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035801A UY35801A (es) 2013-10-29 2014-10-28 Compuesto heterocíclico

Country Status (18)

Country Link
US (1) US9120777B2 (es)
EP (1) EP3063139B1 (es)
JP (1) JP6450755B2 (es)
AR (2) AR098215A1 (es)
CY (1) CY1121279T1 (es)
DK (1) DK3063139T3 (es)
ES (1) ES2710657T3 (es)
HR (1) HRP20190133T1 (es)
HU (1) HUE041792T2 (es)
LT (1) LT3063139T (es)
PL (1) PL3063139T3 (es)
PT (1) PT3063139T (es)
RS (1) RS58321B1 (es)
SI (1) SI3063139T1 (es)
TR (1) TR201901986T4 (es)
TW (1) TWI668214B (es)
UY (1) UY35801A (es)
WO (1) WO2015064083A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6121339B2 (ja) * 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
EP2970331B1 (en) 2013-03-14 2017-05-17 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
CN114981260A (zh) * 2019-12-19 2022-08-30 斯特拉斯堡大学 σ-1受体配体及其用途
CN116354961A (zh) * 2021-12-27 2023-06-30 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
EP1300396B1 (en) 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
MXPA05009771A (es) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
JP2007513082A (ja) 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
EP2054385A2 (en) 2006-08-15 2009-05-06 F. Hoffmann-Roche AG Phenyl, pyridine and quinoline derivatives
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US20080306116A1 (en) 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
TW200918062A (en) 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
AU2010245889A1 (en) 2009-05-07 2011-11-03 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
EP2970331B1 (en) 2013-03-14 2017-05-17 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists

Also Published As

Publication number Publication date
DK3063139T3 (en) 2019-03-11
CY1121279T1 (el) 2020-05-29
PT3063139T (pt) 2019-02-22
HUE041792T2 (hu) 2019-05-28
US9120777B2 (en) 2015-09-01
AR128158A2 (es) 2024-03-27
HRP20190133T1 (hr) 2019-03-22
EP3063139B1 (en) 2018-11-21
TR201901986T4 (tr) 2019-03-21
JP6450755B2 (ja) 2019-01-09
US20150119412A1 (en) 2015-04-30
AR098215A1 (es) 2016-05-18
LT3063139T (lt) 2019-02-25
TWI668214B (zh) 2019-08-11
EP3063139A1 (en) 2016-09-07
WO2015064083A1 (en) 2015-05-07
SI3063139T1 (sl) 2019-03-29
RS58321B1 (sr) 2019-03-29
TW201542539A (zh) 2015-11-16
ES2710657T3 (es) 2019-04-26
PL3063139T3 (pl) 2019-05-31
JP2016535040A (ja) 2016-11-10

Similar Documents

Publication Publication Date Title
DOP2016000206A (es) Compuesto heterocíclico fusionado
CR20160368A (es) Compuesto heterocíclico
UY35774A (es) Compuesto heterocíclico
AR128158A2 (es) Compuesto heterocíclico
CL2017003404A1 (es) Compuestos antibacterianos
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
DOP2015000261A (es) Compuesto peptídico como activador de los receptores del glp-1 y del gip
CR20150205S (es) Almohada de viaje
CL2015003483A1 (es) Composiciones que comprenden tintes fotocrómicos para el tratamiento de superficies.
DK3174868T3 (da) Forbindelser, der er aktive mod bromodomæner
CR20120448A (es) Compuesto heterocíclico
DOP2015000140A (es) Compuesto heterocíclico
CR20140537A (es) Compuesto heterocíclico nitrogenado
UY35322A (es) Compuestos derivados y conjugados de tubulisina, métodos para obtenerlos y uso
CL2016000190A1 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.
CO2017003699A2 (es) Compuesto heterocíclico
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
CL2015002612A1 (es) Oligonucletotidos antisentido para el tratamiento de células madre del cáncer.
UY35650A (es) Compuesto heterocíclico
CL2014002397A1 (es) Polipeptidos para usarse en el tratamiento y/o prevención de una infección fúngica ocasionada por malassezia spp.
ES1102512Y (es) Dispositivo para la aplicacion de acciones terapeuticas sobre el cuerpo.
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
CR20150533A (es) Compuesto peptídico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211215